Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIC1 Injection in R/R B-cell Non-Hodgkin Lymphoma
NCT07456371Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of PIC1 in B-cell non-Hodgkin lymphoma, sponsored by Chongqing Precision Biotech. Primary endpoint: Incidence of Adverse Events at 1 month. Started Mar 2026; status: recruiting.
02
Drugs
PIC1
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07456371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456371.